- What’s behind the proposed pullback on remote patient monitoringCompanies that help doctors keep tabs on their patients at home are freaking out after Medicare's proposal last week to gut remote patient monitoring, or RPM. The plan is a total about-face from…Endpoints · 1d ago↗ source
- Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionPlus, news about Lonza, Bachem and Samsung Biologics. 🤝 Repligen to acquire BioLife Solutions: Repligen will pay around $1.5 billion for cell processing service supplier BioLife, 36% of which w…Endpoints · 1d ago↗ source
- Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 dataWith weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expe…